Recipharm launches its end-to-end inhalation offering

7 May 2019

Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.

Recipharm has launched its end-to-end inhalation offering to provide customers with a fully integrated service from early-stage development through to commercial manufacturing.

Recipharm launches its end-to-end inhalation offering

Recipharm Inhalation Solution offers pharmaceutical companies a seamless outsourcing service for inhalation products, including metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nasal sprays.

The offering follows the acquisition of Sanofi’s inhalation manufacturing business in Holmes Chapel, UK in June 2018, which has specialised in the manufacture of inhalation drug products for over 40 years. The facility is supported by Recipharm’s inhalation development expertise in Research Triangle Park, North Carolina, US.

Commenting on the announcement, Shabbir Mostafa, Global Key Account Director – Inhalations at Recipharm said: “Treatments for respiratory conditions are in high demand, making inhalation products a key growth area for our business. In addition to respiratory diseases, they are now being explored as alternative delivery routes to improve bioavailability and lower the risk of adverse effects, in treating for instance central nervous system conditions. This is making inhalation an interesting area for drug developers”.

“The Recipharm team has a long history in inhalation drug product development and manufacturing. This heritage, combined with market demand, made the launch of Recipharm Inhalation Solutions a logical step for us”.

“Our team has the depth of knowledge required to overcome the challenges associated with developing and manufacturing these types of products. We also understand the hurdles on the path to commercialisation and are well placed to manage complexity and risk along this journey.”

Recipharm Inhalation Solutions™ includes dedicated analytical services for inhalation products, including comprehensive extractable and leachable expertise. A dedicated pilot facility composed of several suites which can replicate commercial processes also assists with the seamless transfer of projects from small to large scale production. In addition, Recipharm has the technical ability to work with different devices, combinations, APIs and suspension formulations.

Read More

Related news

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

18 Jul 2019

Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.

Read more 
Combination technique improves polysaccharide characterization

Combination technique improves polysaccharide characterization

17 Jul 2019

The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.

Read more 
Lubrizol integrates personal, home and health care divisions

Lubrizol integrates personal, home and health care divisions

16 Jul 2019

The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.

Read more 
Bosch finds buyers for its packaging machinery business

Bosch finds buyers for its packaging machinery business

16 Jul 2019

CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".

Read more 
New state-of-the-art cleanroom boosts production of anticancer drugs

New state-of-the-art cleanroom boosts production of anticancer drugs

15 Jul 2019

The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.

Read more 
Colorcon chooses the Netherlands for new starch manufacturing plant

Colorcon chooses the Netherlands for new starch manufacturing plant

12 Jul 2019

The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.

Read more 
GSK opens new continuous manufacturing facilities in Singapore

GSK opens new continuous manufacturing facilities in Singapore

11 Jul 2019

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more